tbuckley/cabot-search huggingface dataset:
Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x)
Authors: Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau
Journal: Journal for ImmunoTherapy of Cancer (2019)
Abstract C20: Smpd3 augments chemotherapy and thwarts PDA progression
Authors: Audrey M. Hendley, Atsushi Urano, Natanya R. Kerper, Phat Duong, Peter Bailey, David K. Chang, Andrew V. Biankin, David W. Dawson, Grace Kim, Robert L. Raffai, Matthias Hebrok
Journal: Cancer Research (2019)

Abstract Deregulated sphingolipid metabolism alters pancreatic cancer progression; for that reason, bioactive lipid signaling molecules such as ceramide show promise as both biomarkers for disease progression and novel therapeutic targets. Intracellular ceramide levels are critical for regulating cellular senescence, apoptosis, and cell cycle arrest in response to stress stimuli such as chemotherapeutics. Our data show Sphingomyelin Phosphodiesterase 3 (Smpd3), a regulator of ceramide synthesis and exosome biogenesis, has a protumorigenic function in pancreatic ductal adenocarcinoma (PDA). Immunodeficient mice orthotopically implanted with Smpd3-deficient PDA cell lines demonstrate significantly reduced tumor burden and longer survival when compared with controls. This observation was mirrored by our KPC; Smpd3f/f mouse model, in which loss of Smpd3 expression significantly correlated with longer survival and decreased metastasis when compared to KPC; Smpd3wt/wt controls. Analysis of SMPD3 in PDA patients revealed that low SMPD3 RNA and protein expression is significantly associated with worse survival. Because chemotherapeutics have been shown to affect expression and function of SMPD3, we stratified patient cohorts into individuals who received adjuvant chemotherapy, more than 95% of which was gemcitabine, and those who did not receive adjuvant chemotherapy. We found that high SMPD3 expression in surgically resected PDA significantly correlated with longer patient survival only in patients receiving adjuvant chemotherapy, and not in the no-adjuvant-chemotherapy group. These data suggest an interaction between adjuvant chemotherapy with gemcitabine and SMPD3 expression. Furthermore, we found that gemcitabine stimulates both the enzymatic activity and expression of SMPD3 in vitro in a panel of human PDA cell lines. Our results suggest a crucial role for SMPD3 in facilitating a protumorigenic environment during PDA progression and implicate SMPD3 as a potential novel biomarker for guiding individualized chemotherapeutic regimens for PDA patients. Citation Format: Audrey M. Hendley, Atsushi Urano, Natanya R. Kerper, Phat Duong, Peter Bailey, David K. Chang, Andrew V. Biankin, David W. Dawson, Grace Kim, Robert L. Raffai, Matthias Hebrok. Smpd3 augments chemotherapy and thwarts PDA progression [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr C20.
Incidence of colorectal premalignant and malignant neoplasm on colonoscopy in an in-patient setting.
Authors: Samira Khan Manji, Zachery Feinberg, Gulam Abbas Manji
Journal: Journal of Clinical Oncology (2012)

e14185 Background: Colorectal cancer (CRC) continues to be a leading cause of death and the third most common cancer in both genders. Numerous studies have shown that routine screening for colon cancer reduces CRC incidence and mortality by detecting premalignant lesions early. Hence screening colonoscopy in the outpatient setting has been the standard of care. In contrast, the incidence of pre-malignant (PMN) and malignant neoplasms (MN) identified during a colonoscopy due to an acute presentation in an in-patient setting is currently unknown. We evaluate the incidence of PMN and MN lesions identified in patients that underwent in-patient colonoscopy for anemia, gastrointestinal bleed (GIB), and or abdominal pain. Methods: A retrospective review of all gastrointestinal consultations (GIC) from January 1st, 2009 until December 31st, 2009 at a single institution. GIC as determined by the requesting provider for anemia, abdominal pain, and/or gastrointestinal bleed (GIB) were included. Results: There were 291 GICs for anemia, abdominal pain, GIB, or a combination thereof resulting in 218 colonoscopies. A total of 15 (6.9%) PMN and MN lesions were identified. Pathological evaluation reveled 13 (86.7%) of these lesions to be consistent with that of adenocarcinoma. The remaining 2 showed squamous cell cancer morphology. PMN/MNs were identified in patients with GIB and anemia (46.7%), anemia alone (20%), GIB and abdominal pain (20%), and GIB alone (13.3%). There was no significant difference in lesions found between genders (46.7% male). Conclusions: Routine outpatient screening colonoscopy is the standard of care with the goal of resecting early stage cancerous lesions resulting in cure. However, there is paucity of data on the incidence of these lesions being identified in an in-patient setting where colonoscopy is performed for GI bleed, anemia, abdominal pain, or a combination thereof. We demonstrate that colonoscopy resulted in identification of PMN/MNs in a significant proportion of patients with afore mentioned specific complaints. Interestingly, most lesions were identified in patients with GIB and anemia, suggesting that a thorough evaluation be undertaken as it may herald an underlying neoplasm.
Updated Guidelines on Screening for Abdominal Aortic Aneurysms
Authors: Julie Ann Freischlag
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Disparities Research, Disparities Researchers, and Health Equity
Authors: Mercedes R. Carnethon, Kiarri N. Kershaw, Namratha R. Kandula
Journal: JAMA (2019)

This Viewpoint discusses the position of the National Institutes of Health (NIH) regarding disparities in health and research and offers recommendations that could hasten progress in eliminating disparities on the basis of race/ethnicity, sex, and socioeconomic status.
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study
Authors: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, Alfredo Rodriguez-Antolin, Susan Feyerabend, Luis Fein, Boris Y. Alekseev, Giri Sulur, Andrew Protheroe, Susan Li, Suneel Mundle, Peter De Porre, Namphuong Tran, Karim Fizazi
Journal: European Urology (2019)
Incidence of maternal peripartum infection: A systematic review and meta-analysis
Authors: Susannah L. Woodd, Ana Montoya, Maria Barreix, Li Pi, Clara Calvert, Andrea M. Rehman, Doris Chou, Oona M. R. Campbell
Journal: PLoS Medicine (2019)

Infection is an important, preventable cause of maternal morbidity, and pregnancy-related sepsis accounts for 11% of maternal deaths. However, frequency of maternal infection is poorly described, and, to our knowledge, it remains the one major cause of maternal mortality without a systematic review of incidence. Our objective was to estimate the average global incidence of maternal peripartum infection.We searched Medline, EMBASE, Global Health, and five other databases from January 2005 to June 2016 (PROSPERO: CRD42017074591). Specific outcomes comprised chorioamnionitis in labour, puerperal endometritis, wound infection following cesarean section or perineal trauma, and sepsis occurring from onset of labour until 42 days postpartum. We assessed studies irrespective of language or study design. We excluded conference abstracts, studies of high-risk women, and data collected before 1990. Three reviewers independently selected studies, extracted data, and appraised quality. Quality criteria for incidence/prevalence studies were adapted from the Joanna Briggs Institute. We used random-effects models to obtain weighted pooled estimates of incidence risk for each outcome and metaregression to identify study-level characteristics affecting incidence. From 31,528 potentially relevant articles, we included 111 studies of infection in women in labour or postpartum from 46 countries. Four studies were randomised controlled trials, two were before-after intervention studies, and the remainder were observational cohort or cross-sectional studies. The pooled incidence in high-quality studies was 3.9% (95% Confidence Interval [CI] 1.8%-6.8%) for chorioamnionitis, 1.6% (95% CI 0.9%-2.5%) for endometritis, 1.2% (95% CI 1.0%-1.5%) for wound infection, 0.05% (95% CI 0.03%-0.07%) for sepsis, and 1.1% (95% CI 0.3%-2.4%) for maternal peripartum infection. 19% of studies met all quality criteria. There were few data from developing countries and marked heterogeneity in study designs and infection definitions, limiting the interpretation of these estimates as measures of global infection incidence. A limitation of this review is the inclusion of studies that were facility-based or restricted to low-risk groups of women.In this study, we observed pooled infection estimates of almost 4% in labour and between 1%-2% of each infection outcome postpartum. This indicates maternal peripartum infection is an important complication of childbirth and that preventive efforts should be increased in light of antimicrobial resistance. Incidence risk appears lower than modelled global estimates, although differences in definitions limit comparability. Better-quality research, using standard definitions, is required to improve comparability between study settings and to demonstrate the influence of risk factors and protective interventions.
Association of Intracranial Atherosclerotic Disease With Brain β-Amyloid Deposition
Authors: Rebecca F. Gottesman, Thomas H. Mosley, David S. Knopman, Qing Hao, Dean Wong, Lynne E. Wagenknecht, Timothy M. Hughes, Ye Qiao, Jennifer Dearborn, Bruce A. Wasserman
Journal: JAMA Neurology (2019)

<h3>Importance</h3> Intracranial atherosclerotic disease (ICAD) is an important cause of stroke and has also been recently identified as an important risk factor for all-cause dementia, but the mechanism of its association with cognitive performance is not fully understood. <h3>Objective</h3> To test the hypothesis that ICAD is associated with cerebral β-amyloid deposition as a marker of Alzheimer disease. <h3>Design, Setting, and Participants</h3> This cross-sectional analysis of data collected from August 2011 through November 2014 was a community-based cohort study conducted in 3 US communities. Of 346 adults without dementia aged 70 to 90 years who were sequentially recruited from 3 of 4 sites of the larger Atherosclerosis Risk in Communities study into a study of brain florbetapir positron emission tomography (ARIC-PET), 300 met inclusion criteria. A total of 589 were approached about recruitment, of whom 346 (58.7%) consented (the remainder either met exclusion criteria for ARIC-PET or refused to participate). Data were analyzed from July 2017 through October 2019. <h3>Exposures</h3> Intracranial atherosclerotic disease presence, frequency, and extent of stenosis, by high-resolution vessel wall magnetic resonance imaging. <h3>Main Outcomes and Measures</h3> Global cortical standardized uptake value ratio (SUVR) of greater than 1.2 as measured by florbetapir PET. Models were conducted using logistic regression methods. In secondary analyses, we tested effect modifications by apolipoprotein E ε4 genotype with interaction terms and in stratified models and evaluated regional patterns of associations. <h3>Results</h3> In 300 participants (mean [SD] age, 76 [5] years; 132 African American individuals [44%], 167 women [56%], and 94 carriers of at least 1 apolipoprotein E ε4 allele [31%]), ICAD was found in 105 participants (35%) and mean (SD) SUVR was higher in individuals with vs without intracranial plaques (1.34 [0.29] vs 1.27 [0.23];<i>P</i> = .03). In adjusted models, ICAD presence (plaque presence [adjusted odds ratio (aOR), 1.20; 95% CI, 0.69-2.07] and frequency [aOR, 1.10; 95% CI, 0.96-1.26]) was not associated significantly with elevated SUVR in the total sample. Furthermore, modest stenosis of the intracranial vessels (defined as &gt;50% stenosis) was not associated with elevated SUVR (aOR, 2.33; 95% CI, 0.82-6.60). <h3>Conclusions and Relevance</h3> In this community-based cohort of adults without dementia, intracranial atherosclerotic plaque or stenosis was not associated with brain β-amyloid deposition.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Authors: Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Ajai Chari, Al-Ola Abdallah, Natalie Callander, Nikoletta Lendvai, Douglas Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward Libby, Bertrand Arnulf, Thierry Facon, Cyrille Hulin, K Martin Kortüm, Paula Rodríguez-Otero, Saad Z Usmani, Parameswaran Hari, Rachid Baz, Hang Quach, Philippe Moreau, Peter M Voorhees, Ira Gupta, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Roxanne C Jewell, Elisha J Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul Richardson, Adam D Cohen
Journal: The Lancet Oncology (2019)
Nonadherence to Any Prescribed Medication Due to Costs Among Adults with HIV Infection — United States, 2016–2017
Authors: Linda Beer, Yunfeng Tie, John Weiser, R. Luke Shouse
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

The United States spends more per capita on prescription drugs than do other high-income countries (1). In 2017, patients paid 14% of this cost out of pocket (2). Prescription drug cost-saving strategies, including nonadherence to medications due to cost concerns, have been documented among U.S. adults (3) and can negatively affect morbidity and, in the case of persons with human immunodeficiency virus (HIV) infection, can increase transmission risk (4,5). However, population-based data on prescription drug cost-saving strategies among U.S. persons with HIV are lacking. CDC's Medical Monitoring Project* analyzed cross-sectional, nationally representative, surveillance data on behaviors, medical care, and clinical outcomes among adults with HIV infection. During 2016-2017, 14% of persons with HIV infection used a prescription drug cost-saving strategy for any prescribed medication, and 7% had cost saving-related nonadherence. Nonadherence due to prescription drug costs was associated with reporting an unmet need for medications from the Ryan White AIDS Drug Assistance Program (ADAP), not having Medicaid coverage, and having private insurance. Persons who were nonadherent because of cost concerns were more likely to have visited an emergency department, have been hospitalized, and not be virally suppressed. Reducing barriers to ADAP and Medicaid coverage, in addition to reducing medication costs for persons with private insurance, might help to decrease nonadherence due to cost concerns and, thus contribute to improved viral suppression rates and other health outcomes among persons with HIV infection.
Reducing overuse in healthcare: the drive to act is strong
Authors: Heather Gallie
Journal: BMJ (2019)

Born and colleagues’ article about the Choosing Wisely campaign brought “action bias” to mind.1 This is the tendency towards action rather than watchful waiting. The phenomenon was studied in penalty shoot-outs of association football games. Statistically the optimal position for the goalkeeper in a penalty shoot-out is the centre of the goal, but keepers always dive, often before the direction …
Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection
Authors: Marco Frigeni, Caroline Besson, Carlo Visco, Helene Fontaine, Maria Goldaniga, Marcella Visentini, Alessandro Pulsoni, Harrys A. Torres, Jan Peveling-Oberhag, Roberto Rossotti, Francesco Zaja, Luigi Rigacci, Michele Merli, Céline Dorival, Camille Alric, Francesco Piazza, Massimo Gentile, Angela Ferrari, Mario Pirisi, Luca Nassi, Sara Rattotti, Annamaria Frustaci, Michele Milella, Emanuele Cencini, Irene Defrancesco, Virginia Valeria Ferretti, Raffaele Bruno, Olivier Hermine, Luca Arcaini
Journal: Leukemia (2019)
Factors that predict pathologic complete response in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Authors: Narendra Hulikal, Joseph Thomas, Donald J. Fernandes, Satadru Ray
Journal: Journal of Clinical Oncology (2013)

e11588 Background: Locally advanced breast cancer (LABC) accounts for 30-60% of all breast cancer patients presenting to the public hospitals in India. The neoadjuvant chemotherapy is reported to achieve a pathological complete response (pCR) rate of 35-60% depending on the receptor subsets and the chemotherapeutic drugs employed. The patients who achieve a pCR are expected to do better in terms of progression free survival. Hence we reviewed our data base to know pCR rates, to compare pCR rates among various receptor subgroups, and to determine the factors which predict pCR. Methods: All patients with LABC (defined as Stage III, AJCC, 7th edition, 2010) and agreed by the hospital tumor board to receive preoperative chemotherapy were included. At each visit, clinical response was assessed according to RECIST criteria. Re-staging work up and mammography were done prior to surgery. Results: Total 84 patients received preoperative chemotherapy. Most common regimen used was 4 courses of AC followed by 4 courses of 3 weekly paclitaxel. Two patients developed systemic metastasis during chemotherapy and were not considered for surgery. Median age was 46 years (ranged from 28 to 66), 46 patients were premenopausal, and 43 % of the tumors were hormone receptor negative. Her 2nu amplification defined as immunohistochemistry 3 + or FISH positive was seen in 27% of patients. Thirty nine patients were stage IIIB, 38 were III A and 5 were IIIC. Total 72 patients completed full course of chemotherapy before surgery. Clinical response was complete in 26, partial in 52, 3 had local progression, one stable and two patient developed distant metastasis (not considered for surgery). Forty eight patients underwent modified radical mastectomy and breast could be conserved in 34 patients. The pCR rate was 36%. Of all the factors (cT status, hormone receptor status, menopausal status, age) cT status was found to be statistically significant factor to predict pCR (p&lt;0.005). Conclusions: Overall pCR rate in the study was 36%, maximum response was noted in ER/PR negative, Her 2nu positive subset. Only factor which was found to be associated with pCR on univariate analysis was cT size.
Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients
Authors: Giacomo Coltro, Abhishek A. Mangaonkar, Terra L. Lasho, Christy M. Finke, Prateek Pophali, Ryan Carr, Naseema Gangat, Moritz Binder, Animesh Pardanani, Martin Fernandez-Zapico, Keith D. Robertson, Alberto Bosi, Nathalie Droin, Alessandro M. Vannucchi, Ayalew Tefferi, Anthony Hunter, Eric Padron, Eric Solary, Mrinal M. Patnaik
Journal: Leukemia (2019)
DSP107-A first in class, bifunctional fusion protein targeting both innate and adaptive immunity
Authors: Adam Foley-Comer, Shirley Greenwald, Ewa Cendrowicz, Rinat Tabakman, Shira Amsili, Alexandra Aronin, Liat Ben-Gigi-Tamir, Elina Zorde-Khvalevsky, Yosi Gozlan, Michal Dranitzki-Elhalel, Ayelet Chajut, Amnon Peled, Edwin Bremer
Journal: Journal for ImmunoTherapy of Cancer (2019)
68Ga–Prostate-Specific Membrane Antigen PET/CT Findings in Extra-axial Metastasis From Prostate Carcinoma
Authors: Mukta Kulkarni, Ajay Vare, Shubhangi Shetkar, Prashant Surkar, Prathamesh Joshi, Kritik Kumar
Journal: Clinical Nuclear Medicine (2019)

Abstract A 67-year-old man with no previous history of malignancy presented with trigeminal neuralgia. MRI of the brain revealed extra-axial lesion along right trigeminal nerve suggestive of neuroma. On histopathology, the lesion was found to be metastasis from adenocarcinoma prostate. Patient underwent 68 Ga–prostate-specific membrane antigen PET/CT for assessing the whole-body status of the disease, which revealed primary prostate lesion, metastatic bone lesions, and extra-axial lesion along the right trigeminal nerve. Extra-axial, intracranial metastasis from prostate carcinoma is an uncommon phenomenon. We describe 68 Ga–prostate-specific membrane antigen PET/CT findings in an exceedingly rare case of extra-axial metastatic lesion from prostate carcinoma.
Response to: ‘New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion’ by Sacre <i>et al</i>
Authors: Martin Aringer, Karen Costenbader, Thomas Dörner, Sindhu R Johnson
Journal: Annals of the Rheumatic Diseases (2019)

In their letter, Dr Sacre and colleagues1 describe an interesting retrospective study on 129 patients with pericardial effusion, of whom 17 were diagnosed with systemic lupus erythematosus (SLE). The authors arrive at a reassuring sensitivity of 100% for the new European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria.2 3 However, specificity was clearly lower at 84%, below the specificity of the ACR and the Systemic Lupus International Collaborating Clinics (SLICC) criteria. The latter is a somewhat unexpected result. Based on the …